Form 4: Belite Bio CSO Executes Planned ADS Sale

Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of Belite Bio, Inc. pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., sold a total of 1,000 American depositary shares (ADS) on April 17, 2026.
• The transactions were executed in six separate tranches at weighted average prices ranging from $158.46 to $163.33 per share.
• Following these transactions, the reporting person retains beneficial ownership of 13,666 shares.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents a routine divestment by an executive.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• Insider selling, even when planned, reduces the direct equity stake held by a key member of the scientific leadership team.

Risks

• Continued reliance on Rule 10b5-1 plans by executives may be perceived by some investors as a lack of long-term holding conviction, though this is a standard practice.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling in the biotechnology sector is common among executives for liquidity and diversification purposes, particularly when executed via pre-planned 10b5-1 arrangements.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining compliance with SEC regulations.
• The volume of shares sold (1,000) is relatively minor compared to typical executive holdings in mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sale was conducted through a pre-planned, automated trading program.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Belite Bio, BLTE, Insider Trading, Form 4, Biotech, Rule 10b5-1